{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG221&page=2", "query": { "intervention": "AG221", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AG221&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T12:03:43.100Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03723057", "title": "Expanded Access for AG-221", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "AG-221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2019-10-24", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 1, "location_summary": "Summit, New Jersey", "locations": [ { "city": "Summit", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03723057" }, { "nct_id": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed Acute Myeloid Leukemia (AML)", "Untreated AML", "AML Arising From Myelodysplastic Syndrome (MDS)", "AML Arising From Antecedent Hematologic Disorder (AHD)", "AML Arising After Exposure to Genotoxic Injury" ], "interventions": [ { "name": "AG-120", "type": "DRUG" }, { "name": "AG-221", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2015-12-31", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632708" }, { "nct_id": "NCT05102370", "title": "A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clonal Cytopenia of Undetermined Significance", "CCUS Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-10-06", "completion_date": "2026-01-26", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 12, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Basking Ridge, New Jersey + 9 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05102370" }, { "nct_id": "NCT06756308", "title": "A Study of Enasidenib in People With T-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Lymphoma" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2024-12-24", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06756308" }, { "nct_id": "NCT01915498", "title": "Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2013-08-27", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 19, "location_summary": "Duarte, California • Stanford, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01915498" }, { "nct_id": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Leukemia, Acute Myeloid", "Myeloid Leukemia, Acute", "Leukemia, Myeloid, Acute", "Acute Myelogenous Leukemia", "Leukemia, Acute Myelogenous", "Myelogenous Leukemia, Acute", "AML", "Bone Marrow Transplant" ], "interventions": [ { "name": "Iomab-B", "type": "DRUG" }, { "name": "Conventional Care", "type": "DRUG" }, { "name": "HCT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Actinium Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 153, "start_date": "2016-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 22, "location_summary": "Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02665065" }, { "nct_id": "NCT04203316", "title": "Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Enasidenib Mesylate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "24 Months to 21 Years" }, "enrollment_count": 1, "start_date": "2023-08-14", "completion_date": "2026-10-03", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT04203316" }, { "nct_id": "NCT03515512", "title": "IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-07-17", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515512" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT03728335", "title": "Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Enasidenib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-12-23", "completion_date": "2027-01-11", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-22T12:03:43.100Z", "location_count": 2, "location_summary": "Duarte, California • Tampa, Florida", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03728335" } ] }